Pfizer, Inc. · NYSE:PFE

Pfizer — 43rd Annual TD Cowen Health Care Conference 2023

7 slides from Pfizer's conference presentation, Mar 7, 2023

  1. Slide 1: 43rd Annual TD Cowen Health Care Conference

    43rd Annual TD Cowen Health Care Conference March 7, 2023 Breakthroughs that change patients' lives ®

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements  Our discussions during this presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We may include forward-lookin

  3. Slide 3: Anticipated Long-Term Growth Excluding COVID-19 Products

    Anticipated Long-Term Growth Excluding COVID-19 Products Illustrative* ~$84B ~$25B4 $XB5 '25-'30 CAGR 10% ~$52B1 '22-'25 CAGR 6% ~$70B '25-'30 CAGR 6% with new launches ~$20B3 New launches ~$17B2 Current products *For illustrative purposes only and not intended to be at scale. All values at constant

  4. Slide 4: Appendix

    Appendix

  5. Slide 5: Key Products Included in the Expected ~$17 Billion in LOE Revenue Declines from 2025-2030

    Key Products Included in the Expected ~$17 Billion in LOE Revenue Declines from 2025-2030 2021 WW 2021 U.S. 2021 Dev. EU Year of Year of Revenues Revenues Revenues Expected U.S. Expected EU Product ($ millions) ($ millions) ($ millions) LOE LOE Eliquis1 $5,970 $3,160 $1,520 2026* 2026 Inlyta $1,002

  6. Slide 6: New Launches / Co-promotions and Potential Product Launches

    New Launches / Co-promotions and Potential Product Launches1 ~$20B Potential Revenue ~$25B Potential Revenue expected for NME and expected from new new indications by 20302 BD deals by 20303 Vaccines Inflammation/Immunology Oncology Rare Disease Internal Medicine New Molecular Entity (NME) Launches

  7. Slide 7: Additional Pipeline Potential Launches Through 2030 – Selected Examples

    Introduction Additional Pipeline Potential Launches Through 2030 – Selected Examples Product Candidate Anticipated Indication(s) Expected Potential Launch New Molecular Entity (NME) Launches Danuglipron or PF’1532 (oral GLP1s) Type 2 Diabetes, Obesity >2024 Anti-IFN-β Antibody (PF’3859) Dermatomyosi

Pfizer — 43rd Annual TD Cowen Health Care Conference 2023 on 6ix